 Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases Detect program to facilitate faster diagnoses for children with lysosomal storage disorders LSDs, including GM1 gangliosidosis and GM2 gangliosidosis, also known as Tay-SachsSandhoff disease. LSDs are progressive, multi-system, inherited metabolic diseases associated with premature death, and genetic testing is a crucial first step to arriving at a diagnosis. 